SCHEMBL21200326

SCHEMBL21200326

Cn1cnnc1CC1(c2cccc(NC(=O)c3cc(CN4CCC5CC54)cc(C4CC4)n3)c2)COC1

nearest known ligand 0.72

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CBLB Q13191 20/20 0.72
▸ CBLC Q9ULV8 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29866735 1.00 CBLB (0.72) CBLBCBLC
SCHEMBL29866927 0.89 CBLB (0.78) CBLBCBLC
SCHEMBL21200878 0.89 CBLB (0.78) CBLBCBLC
SCHEMBL21200263 0.87 CBLB (0.83) CBLBCBLC
SCHEMBL29867060 0.87 CBLB (0.83) CBLBCBLC
SCHEMBL31099573 0.86 CBLB (0.70) CBLBCBLC
SCHEMBL26918504 0.86 CBLB (0.70) CBLBCBLC
SCHEMBL26918498 0.86 CBLB (0.70) CBLBCBLC
SCHEMBL21212485 0.86 CBLB (0.81) CBLBCBLC
SCHEMBL29866800 0.86 CBLB (0.81) CBLBCBLC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3743063-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF Nurix Therapeutics, Inc. (US) 2020-12-02 — — EP disclosed
WO-2019148005-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF NURIX THERAPEUTICS, INC. (US) 2019-08-01 — — WO disclosed
Send feedback